Sanofi Gets Into Generics Game

Image via Wikipedia

Sanofi-Aventis plans to make a $2.57 billion (10% premium) offer for Czech generic drugmaker Zentiva, trumping a bid from financial group PPF. Sanofi’s move on Zentiva follows Daiichi Sankyo’s $4.6B offer for India’s top generic company, Ranbaxy.
Generic drug production has traditionally been shunned by large pharmaceutical companies but is now receiving increased interest [...]

Daiichi Sankyo Goes Generic with Ranbaxy Purchase

Image via Wikipedia

The generic drug business is growing twice as fast as branded medicines so it is no wonder that J&J, Novartis (with the purchase of Hexal and Eon to form Sandoz) and now Daiichi Sankyo are interested.
Daiichi Sankyo announced today that they will buy a controlling interest (50.1%) in India’s Ranbaxy Laboratories for ~$4.6B, [...]

TEVA Gets Taste of Own Medicine

The Israeli generic drug maker, known for its aggressive tactics is getting a taste of its own medicine if Pittsburgh based, Mylan has anything to say about it (I can’t get enough of the: “taste of its own medicine line”).
TEVA markets a proprietary, branded drug for MS called glatiramer acetate (COPAXONE), sold $1.7B worth of [...]